Drug
Interferon beta-1a clinical trials
Also written Avonex, Rebif and Interferon-beta-1a.
- studies test it
- 82
- open now
- 2
- in phase 3
- 20
- first study started
- 1999
Keep track of what changes. Save the Interferon beta-1a studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
82 studies that test it; most in 2004 (10)
| Year | Studies |
|---|---|
| 1999 | 3 |
| 2001 | 4 |
| 2002 | 4 |
| 2003 | 6 |
| 2004 | 10 |
| 2005 | 6 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2020 | 9 |
| 2021 | 3 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 24
- Phase 3
- 20
- Phase 4
- 24
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 10
Who runs them
Industry 58 · Other 24
Biogen (23) · Merck KGaA, Darmstadt, Germany (11) · EMD Serono (8) · Synairgen Research Ltd. (5) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Shahid Beheshti University of Medical Sciences (3) · Faron Pharmaceuticals Ltd (3) · Biocad (2)
Often tested with
Tested in the same studies.
Remdesivir (4) · Interferon Beta-1a Inhalation Solution SNG001 (4) · Lopinavir-ritonavir drug combination (3) · Hydroxychloroquine (3) · Interferon beta-1b (3) · Peginterferon beta-1a (3) · Glatiramer (3) · Methylprednisolone (3)
Studies
Open first, then newest update. How each study uses Interferon beta-1a is read from its arms, and is right about nine times in ten.
Testing it · 82
- Early Interferon-beta Treatment for West-Nile Virus InfectionRecruitingPhase 2Tel-Aviv Sourasky Medical CenterNCT06510426Written as Rebif 44 MCG Per 0.5 ML Prefilled Syringe
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Interferon beta-1a
- Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral InfectionTerminatedPhase 2Synairgen Research Ltd.NCT06999603Written as SNG001
- Trial of Treatments for COVID-19 in Hospitalized AdultsCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT04315948Written as Interferon Beta-1A
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedPhase 3Tanabe Pharma CorporationNCT01753570Written as IFN beta(24 weeks)
- ACTIV-2: A Study for Outpatients With COVID-19CompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT04518410Written as SNG001
- Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWithdrawnPhase 1/2Fred Hutchinson Cancer CenterNCT05936229Written as Interferon Beta-1A
- A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnPhase 4BiogenNCT00771043Written as TYSABRI and AVONEX
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A ProductsCompletedPhase 1Food and Drug Administration (FDA)NCT04183491Written as Interferon beta-1a
- Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19TerminatedPhase 2Faron Pharmaceuticals LtdNCT04860518Written as IFN beta-1a
- Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19CompletedPhase 3Synairgen Research Ltd.NCT04732949Written as SNG001
- Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple SclerosisCompletedPhase 2/3BiocadNCT02727907Written as BCD-033 (interferon beta 1a)
- Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) InfectionCompletedPhase 2Synairgen Research Ltd.NCT04385095Written as SNG001
- A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or InfluenzaCompletedPhase 2Synairgen Research Ltd.NCT03570359Written as Interferon Beta-1A
- Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple SclerosisCompletedPhase 4Louisiana State University Health Sciences Center ShreveportNCT00246324Written as Interferon beta 1a, oral doxycycline
- Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple SclerosisCompletedPhase 3CinnagenNCT05242133Written as Pegylated interferon beta-1a
- Adaptive COVID-19 Treatment Trial 3 (ACTT-3)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04492475Written as Interferon beta-1a
- Public Health Emergency: SOLIDARITY TRIAL PhilippinesCompletedNot applicableUniversity of the PhilippinesNCT05024006Written as Interferon beta-1a
- World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 TreatmentsStatus unknownPhase 3The University of The West IndiesNCT04647669Written as Interferon beta-1a
- Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAATerminatedPhase 2Faron Pharmaceuticals LtdNCT03119701Written as Interferon Beta-1A
See all 82 studies that test Interferon beta-1a →
Given in every arm · 11 — Interferon beta-1a is usual care beside what is tested
- Nivolumab in Children and Adults With Nasopharyngeal CarcinomaRecruitingPhase 2German Society for Pediatric Oncology and Hematology GPOH gGmbHNCT06019130Written as Interferon beta-1a
- National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple SclerosisCompletedPhase 3Rennes University HospitalNCT02937285Written as Interferon beta 1a
- Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis PatientsStatus unknownPhase 2German University in CairoNCT05298670Written as Interferon beta-1a
- A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)TerminatedPhase 2Merck KGaA, Darmstadt, GermanyNCT03387046Written as IFN beta-1a
- Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1aCompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT01514370Written as IFN beta 1a 44 mcg TIW
- A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyCompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT01198132Written as Rebif
- Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With AvonexCompletedPhase 2BiogenNCT01864148Written as Avonex
- Neuroprotection With Riluzole Patients With Early Multiple SclerosisCompletedPhase 2University of California, San FranciscoNCT00501943Written as Avonex (Interferon beta 1a)
- Combination Therapy Using Cellcept and Rebif in RRMSCompletedEarly Phase 1Aaron BosterNCT00618527Written as human interferon beta 1a (Rebif)
- Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple SclerosisCompletedPhase 2SanofiNCT00489489Written as Interferon-β
- Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple SclerosisCompletedPhase 4BiogenNCT00492765Written as Interferon-beta-1a
As the comparator · 26 — what is tested is compared with Interferon beta-1a
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisActive, not recruitingPhase 3BiogenNCT03958877Written as Interferon beta type 1a
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT01892722Written as Interferon beta-1a
- Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedPhase 3BiogenNCT02283853Written as Interferon β-1a
- A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple SclerosisCompletedPhase 2Genentech, Inc.NCT00676715Written as Avonex
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedPhase 3Hoffmann-La RocheNCT01412333Written as Interferon beta-1a
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedPhase 3Hoffmann-La RocheNCT01247324Written as Interferon beta-1a
- BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00605215Written as Avonex®
- A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)WithdrawnPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01975298Written as Avonex®
- Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple SclerosisCompletedPhase 2/3BiocadNCT02744222Written as Avonex®
- Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)TerminatedPhase 3EMD Serono Research & Development Institute, Inc.NCT04032158Written as Avonex®
- Study of Evobrutinib in Participants With RMSTerminatedPhase 3EMD Serono Research & Development Institute, Inc.NCT04032171Written as Avonex®
- Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisCompletedPhase 3CelgeneNCT02047734Written as Interferon beta-1a
- Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)CompletedPhase 3CelgeneNCT02294058Written as Interferon beta-1a
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoCompletedPhase 3Genzyme, a Sanofi CompanyNCT00548405Written as Interferon beta-1a
- Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy VolunteersCompletedPhase 1BiocadNCT02359877Written as Rebif
- Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisCompletedPhase 3BiogenNCT01064401Written as Interferon beta-1a
- A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple SclerosisCompletedPhase 3SanofiNCT00883337Written as Interferon β-1a
- Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple SclerosisWithdrawnPhase 2Revalesio CorporationNCT01714089Written as Interferon beta 1a
- Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on TeriflunomideCompletedPhase 2SanofiNCT01403376Written as Interferon-β-1
- Phase I BP Interferon (IFN) Beta-004CompletedPhase 1Centre Hospitalier Universitaire VaudoisNCT02517788Written as Interferon beta-1a original
Showing 20 of 26.
Codes
What other systems call Interferon beta-1a · ClinicalTrials.gg INT006515
- MeSH (NLM) D000068556Interferon beta-1aConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) XRO4566Q4RINTERFERON BETA-1AConfirmed FDA, NLM, Wikidata
- RxNorm 75917Confirmed FDA, Wikidata
- Wikidata Q2450337interferon beta-1aConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1823Interferon Beta-1AOne source FDA
- DrugBank DB00060One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068556 | Interferon beta-1a | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | XRO4566Q4R | INTERFERON BETA-1A | Confirmed FDA, NLM, Wikidata |
| RxNorm | 75917 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2450337 | interferon beta-1a | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1823 | Interferon Beta-1A | One source FDA |
| DrugBank | DB00060 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.